Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACAD is in the long-term up 1174% in 15 years.
Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-2.61||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-85.71%||Sales Growth - Q/Q||-91.67%||P/E||-10.38|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-38.09%||ROE||-40.35%||ROI|
|Current Ratio||18.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||-123217%||Net Profit Margin||-122364%||Dividend Payout Ratio|
|Cash From Financing Activities||1.44 M||Cash From Investing Activities||38.47 M||Cash From Operating Activities||-25.35 M||Gross Profit|
|Net Profit||-40.38 M||Operating Profit||-40.55 M||Total Assets||301.96 M||Total Current Assets||299.9 M|
|Total Current Liabilities||16.65 M||Total Debt||Total Liabilities||16.87 M||Total Revenue|
|High 52 week||39.14||Low 52 week||15.12||Last close||17.87||Last change||1.53%|
|RSI||52.92||Average true range||0.66||Beta||1.75||Volume||3.38 M|
|Simple moving average 20 days||0.08%||Simple moving average 50 days||-2.47%||Simple moving average 200 days||-35.73%|
|Performance Week||2.47%||Performance Month||-2.14%||Performance Quart||-30.98%||Performance Half||-40.61%|
|Performance Year||-34.78%||Performance Year-to-date||-40.65%||Volatility daily||1.95%||Volatility weekly||4.36%|
|Volatility monthly||8.94%||Volatility yearly||30.98%||Relative Volume||1230.89%||Average Volume||2.95 M|
|New High||New Low|
2019-09-17 23:00:00 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock
2019-09-17 16:02:00 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
2019-09-17 15:25:42 | 5 Top Stock Trades for Wednesday: BA, ACB, PINS
2019-09-11 10:23:43 | 3 Hot Biotechs with High Upside Potential
2019-09-10 11:41:03 | ACADIA Surges on Early Success of Nuplazid Dementia Study
2019-09-10 10:59:02 | Will ACADIA Continue to Surge Higher?
2019-09-10 08:39:00 | Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?
2019-09-09 17:38:00 | Why Acadia Pharmaceuticals Stock Skyrocketed Today
2019-09-09 16:55:24 | ACADIA Pharmaceuticals Help Lift Biotech ETFs
2019-09-09 16:26:30 | Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High
2019-09-09 16:13:00 | What Happened in the Stock Market Today
2019-09-09 12:17:30 | A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019
2019-09-09 10:26:18 | Options Hot as ACADIA Pharmaceuticals Stock Soars
2019-09-09 09:05:01 | ACADIA Enters Oversold Territory
2019-09-09 07:31:00 | [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment
2019-09-09 06:30:00 | ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
2019-08-29 12:47:04 | Top Ranked Momentum Stocks to Buy for August 29th
2019-08-26 08:39:12 | Top Ranked Momentum Stocks to Buy for August 26th
2019-08-23 11:44:03 | Top Ranked Momentum Stocks to Buy for August 23rd
2019-08-20 08:34:12 | Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
2019-08-16 10:42:02 | Palatin's PTN to Report Q4 Earnings: What's in the Cards?
2019-08-15 09:43:01 | Top Ranked Momentum Stocks to Buy for August 15th
2019-08-14 11:09:03 | Top Ranked Momentum Stocks to Buy for August 14th
2019-08-12 09:09:01 | Top Ranked Momentum Stocks to Buy for August 12th
2019-08-06 08:08:12 | ACADIA Pharmaceuticals Inc. ACAD Shares March Higher, Can It Continue?
2019-08-02 11:28:09 | Edited Transcript of ACAD earnings conference call or presentation 31-Jul-19 8:30pm GMT
2019-08-01 12:06:06 | Why Acadia Pharmaceuticals Stock Is Crushing It Today
2019-08-01 06:00:00 | Acadia Pharmaceuticals Beats Expectations in Q2
2019-08-01 02:24:23 | Acadia Pharmaceuticals ACAD Q2 2019 Earnings Call Transcript
2019-07-31 18:55:10 | Acadia Pharmaceuticals ACAD Reports Q2 Loss, Tops Revenue Estimates
2019-07-31 16:05:00 | ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
2019-07-31 14:30:00 | ACADIA Pharmaceuticals, Inc. to Host Earnings Call
2019-07-23 11:38:00 | Why Acadia Pharmaceuticals Is Tanking Today
2019-07-23 11:00:00 | Are These 2 Beaten-Down Biotech Stocks Worth Buying?
2019-07-23 07:36:34 | Why Is Acadia Pharmaceuticals Falling Today?
2019-07-22 16:53:00 | Acadia stock drops as schizophrenia drug doesn't pass clinical trial
2019-07-22 16:44:49 | Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%
2019-07-22 16:14:45 | Acadia's schizophrenia treatment fails to meet main goal of late-stage study
2019-07-22 13:56:00 | Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study